Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON-1 in wet AMD
NCT03452527Phase 2Terminated
- Sponsor
- Iconic Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- Apr 2019
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ICON-1 in exudative macular degeneration (2 arms), sponsored by Iconic Therapeutics, Inc. Primary endpoint: Change in Choroidal Neovascularization Over Time at Month 9. Started Mar 2018; status: terminated.
02
Drugs
ICON-1
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03452527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452527.